Skip to main content
OpenTrials
Completed

NCT Number: NCT02158858

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Phase 1 Part: This was an open-label, sequential dose escalation study of pelabresib (CPI-0610) in patients who had previously been treated for Acute Leukemia, Myelodysplastic/Myeloproliferative Neoplasms.

Phase 2 Part: This was an open-label study of pelabresib (CPI-0610), administered with and without Ruxolitinib, in patients diagnosed with Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia).

Pelabresib (CPI-0610) was a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Myelofibrosis Blood Coagulation Disorders Blood Platelet Disorders Bone Marrow Disease Bone Marrow Diseases Essential Thrombocytosis Hematologic Diseases Hematological Disease Hemic and Lymphatic Diseases Hemorrhagic Disorders Leukemia Leukemia, Myelocytic, Acute Leukemia, Myeloid Leukemia, Myeloid, Acute Myelodysplastic Syndrome (MDS) Myelodysplastic Syndromes Myelodysplastic-Myeloproliferative Diseases Myelodysplastic/Myeloproliferative Neoplasm Myeloproliferative Disorders Neoplasms Neoplasms by Histologic Type Precancerous Conditions Preleukemia Primary Myelofibrosis Thrombocythemia, Essential Thrombocytosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

UZ Leuven - Campus Gasthuisberg, Leuven, Viaams Braban, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Phase I (Dose Escalation) - Inclusion and Exclusion Criteria:

  • Inclusion Criteria (Phase I):
  • Age: Adults ≥18 years.
  • Diagnosis: Histologically or cytologically confirmed diagnosis of one of the following hematologic malignancies:
  • Acute myelogenous leukemia (AML)
  • Acute lymphocytic leukemia (ALL)
  • Acute undifferentiated or biphenotypic leukemia
  • Chronic myeloid leukemia (CML) in blast crisis
  • Myelodysplastic syndrome (MDS)
  • Myelodysplastic/myeloproliferative neoplasms (MDS/MPN)
  • Myelofibrosis (MF)
  • Performance Status: ECOG ≤2.
  • Organ Function:
  • Serum total bilirubin ≤1.5 × ULN
  • AST/ALT ≤2.5 × ULN (up to 5 × ULN if due to leukemic infiltration)
  • Serum creatinine ≤2.0 × ULN or CrCl ≥30 mL/min
  • Hematology (MF only):
  • Platelet count ≥50 × 10⁹/L and ANC ≥1 × 10⁹/L (MF not on ruxolitinib)
  • Platelet count ≥75 × 10⁹/L and ANC ≥1 × 10⁹/L (MF on ruxolitinib)
  • Other:
  • DIPSS-plus risk category of intermediate-2 or high (MF only)
  • Serum glucose ≤160 mg/dL (or HbA1C ≤7%)
  • Fully recovered from major surgery and acute toxic effects of prior therapy
  • Negative pregnancy test for women of childbearing potential
  • Agreement to use appropriate contraception
  • Written informed consent
  • Exclusion Criteria (Phase I):
  • Untreated newly diagnosed acute leukemia (unless AML with myelodysplasia-related changes and 20-30% blasts)
  • Relapsed/refractory acute leukemia where further induction chemotherapy is beneficial
  • Acute leukemia relapse <6 months after allogeneic SCT
  • CML in blast crisis treated with only one TKI
  • Very low/low risk MDS without prior treatment
  • CNS involvement by leukemia (unless resolved)
  • Active HIV, Hepatitis B or C infection
  • GI impairment affecting absorption (unresolved nausea, vomiting, diarrhea >CTCAE grade 1)
  • Significant cardiac disease (recent MI/angina, high cTn, QTcF >470 ms, LVEF <50%, uncontrolled arrhythmia, etc.)
  • Severe/uncontrolled comorbidities
  • Recent systemic anti-cancer therapy (other than hydroxyurea/radiotherapy) <2 weeks prior
  • Ongoing or recent JAK inhibitor use (<2 weeks prior, MF only)
  • Recent therapeutic antibody (<4 weeks) or investigational agent (<2 weeks or <5 half-lives)
  • Use of strong CYP450 inhibitors/inducers or drugs with Torsades de Pointes risk
  • Immunosuppressive treatment that cannot be discontinued
  • Pregnant/lactating women
  • Inadequate contraception
  • Inability/unwillingness to comply with protocol

Phase II (Expansion) - Inclusion & Exclusion Criteria:

  • Inclusion Criteria (Phase II):
  • MF Arms (Prior JAKi, Add-on JAKi, JAKi Naïve)
  • Age: Adults ≥18 years
  • Diagnosis: Confirmed primary MF or MF evolved from ET or PV
  • Risk: DIPSS intermediate-2 or higher
  • Platelets:
  • ≥75 × 10⁹/L (Arms 1 & 2)
  • ≥100 × 10⁹/L (Arm 3, JAKi naïve)
  • ANC: ≥1 × 10⁹/L
  • Spleen Volume: ≥450 cm³ by MRI/CT (non-TD cohorts) OR
  • Transfusion Dependence: Average ≥2 RBC transfusions/month (total ≥6 in prior 12 weeks) for TD cohorts
  • Peripheral Blood Blasts: <10%
  • Symptoms: At least 2 symptoms measurable (score ≥1 for Arms 1 & 2; score ≥3 or total ≥10 for Arm 3) using MFSAF v4.0
  • Treatment History:
  • Arm 1 (Prior JAKi): Previously treated with JAKi and intolerant, resistant, refractory, or lost response, or ineligible for JAKi
  • Arm 2 (Add-on JAKi): On ruxolitinib ≥6 months, stable dose ≥8 weeks, not adequately controlled
  • Arm 3 (JAKi Naïve): No prior JAKi, eligible for ruxolitinib
  • Performance Status: ECOG ≤2
  • Organ Function: Serum direct bilirubin <2 × ULN, AST/ALT ≤2.5 × ULN (up to 5 × ULN if due to liver involvement), CrCl ≥45 mL/min
  • Other: Fully recovered from major surgery/acute toxic effects, effective contraception, written informed consent
  • ET Arm (High-Risk ET)
  • Age: Adults ≥18 years
  • Diagnosis: Confirmed ET (WHO 2016 criteria)
  • High-Risk: At least one of:
  • Age >60 years
  • Platelets >1500 × 10⁹/L
  • Prior thrombosis, erythromelalgia, or migraine (disease-related)
  • Prior hemorrhage related to ET
  • Diabetes/hypertension requiring therapy >6 months
  • Symptoms: ≥2 symptoms with average score ≥3 or total score ≥15 (MPN-SAF)
  • Platelets: >600 × 10⁹/L
  • Resistant/Intolerant to HU: As defined by ELN
  • Performance Status: ECOG ≤2
  • Life Expectancy: >24 weeks
  • ANC: ≥1 × 10⁹/L
  • Organ Function: Serum direct bilirubin <2 × ULN, AST/ALT ≤2.5 × ULN, CrCl ≥45 mL/min
  • Other: Fully recovered from major surgery/acute toxic effects, effective contraception, written informed consent
  • Exclusion Criteria (Phase II)
  • Prior splenectomy (MF non-TD cohorts)
  • Splenic irradiation within 3 months
  • Active or chronic HIV, Hepatitis B/C infection
  • Active clinically significant infection (until recovery ≥2 weeks)
  • Anemia deemed clinically significant (iron/B12/folate deficiency, hemolytic anemia)
  • Major bleeding event (≥2 g/dL Hgb drop or ≥2 units transfused in last 6 months)
  • Liver cirrhosis Child-Pugh B or C
  • GI impairment affecting absorption (unresolved nausea, vomiting, diarrhea >CTCAE grade 1)
  • Rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (Arm 3)
  • Hypersensitivity to ruxolitinib formulation (Arm 3)
  • History of PML (Arm 3)
  • Significant cardiac disease (recent MI/angina, QTcF >500 ms [>450 ms in France/Germany], uncontrolled arrhythmia, etc.)
  • Ongoing uncontrolled hypertension
  • Severe/uncontrolled comorbidities
  • Systemic anticancer treatment (other than ruxolitinib for Arm 2, HU/ANA up to 24h prior) <2 weeks or <5 half-lives prior
  • Prior treatment with any BET inhibitor
  • Hematopoietic growth factor or androgenic steroids <4 weeks prior
  • Systemic corticosteroids ≥10 mg prednisone equivalent within 4 weeks (exceptions for short courses)
  • Concurrent/second malignancy (except certain adequately treated cancers)
  • Pregnant/lactating women, or planning pregnancy within protocol-defined window
  • Inability/unwillingness to comply with protocol

Treatment and study plan

Pelabresib

Drug

CPI-0610 was administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)

Other names: CPI-0610, DAK539

Ruxolitinib

Drug

Ruxolitinib was given orally, twice daily (BID), on a continuous basis for 21 consecutive days of each 21-day cycle.

Primary outcomes

  1. Phase 1: Frequency of Dose-limiting Toxicities (DLTs)

    Time frame: Up to 21 days

    A dose-limiting toxicity (DLT) was defined as an adverse event or abnormal laboratory value assessed by the Investigator as unrelated to disease progression, intercurrent illness, or concomitant medications that occurred within the first cycle of treatment (21-day cycle) with pelabresib (CPI-0610), and that met any of the criteria specified in the protocol.

  2. Phase 2 (Cohorts 1B, 2B, and Arm 3): Number of Participants With Splenic Response Rate (SVR35) at Week 24

    Time frame: Week 24 (Cycle 9 Day 1)

    Splenic Response Rate (SVR35) at Week 24 was defined as the proportion of participants who demonstrated a reduction of at least 35% in spleen size from baseline, as measured by imaging techniques (MRI or CT), following 24 weeks of treatment.

  3. Phase 2 (Cohorts 1A and 2A): Number of Participants Enrolled as Transfusion Dependent (TD) With Conversion Rate From Red Blood Cell (RBC) Transfusion Dependence (TD) to Transfusion Independence (TI)

    Time frame: Any 12 consecutive weeks (rolling window) during active treatment with pelabresib (CPI-0610), from first dose through treatment discontinuation (up to approximately 8 years for Phase II)

    Conversion rate was defined as the proportion of participants who converted from transfusion dependence (TD) to transfusion independence (TI). TD was characterized by receiving an average of at least 2 units of red blood cell (RBC) transfusions per month-amounting to a minimum of 6 units over the 12 weeks prior to enrollment-while TI was defined as the absence of RBC transfusions during any consecutive 12-week period.

  4. Phase 2 (Arm 4): Number of Participants With Complete Hematological Response (CHR) Rate

    Time frame: Over 2 consecutive cycles (rolling window) (1 cycle = 21 days)

    Complete Hematological Response (CHR) Rate was defined as the proportion of participants who fulfilled the criteria for CHR, based on the modified European LeukemiaNet (ELN) guidelines (Barosi et al 2009): platelet count ≤400 × 10⁹/L, white blood cell (WBC) count ≤10 × 10⁹/L, confirmation of laboratory values after one treatment cycle, and normal spleen size determined by palpation or imaging.

Secondary outcomes

  1. Phase 1: Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria

    Time frame: Up to approximately 6 months

    The distribution of adverse events was performed through the analysis of frequencies for treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs), based on the monitoring of relevant clinical and laboratory safety parameters. Treatment-emergent adverse events (TEAEs) in this study were defined as events that began after the first dose of study treatment and continued until 30 days after the last dose, or events that were present prior to the first dose and increased in severity based on preferred term within 30 days following the last dose of pelabresib (CPI-0610).

  2. Phase 2 (All Arms): Number of Adverse Events and Serious Adverse Events as Assessed by CTCAE Criteria

    Time frame: Up to approximately 387 weeks

    The distribution of adverse events was performed through the analysis of frequencies for treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs), based on the monitoring of relevant clinical and laboratory safety parameters. Treatment-emergent adverse events (TEAEs) in this study were defined as events that began after the first dose of study treatment and continued until 30 days after the last dose, or events that were present prior to the first dose and increased in severity based on preferred term within 30 days following the last dose of pelabresib (CPI-0610).

  3. Phase 2 (All Arms): Symptom Improvement From the Patient Global Impression of Change (PGIC) at 12 and 24 Weeks

    Time frame: Week 12 (Cycle 5 Day 1), Week 24 weeks (Cycle 9 Day 1)

    The Patient Global Impression of Change (PGIC) was a single-question, patient-reported assessment that asked individuals to rate their overall change in myeloproliferative neoplasm (MPN) symptoms since starting study treatment. The participants selected one of seven options, ranging from 'Very much improved' to 'Very much worse'. 'No Change from Baseline' indicated stable symptoms (no improvement or worsening), negative change from Baseline indicated a reduction in symptom severity (improvement), and positive change from Baseline indicated an increase in symptom severity (worsening).

  4. Phase 2 (Arms 1, 2 and 3): Percent Change From Baseline in Total Symptom Score (TSS) From the Myelofibrosis Symptom Assessment Form (MFSAF v4.0) at 12 and 24 Weeks

    Time frame: Baseline, Week 12 (Cycle 5 Day 1), Week 24 (Cycle 9 Day 1)

    The MFSAF (Myelofibrosis Symptom Assessment Form) was completed by participants every day for 7 days before Day 1 of each treatment cycle, including the 7 days before starting Cycle 1. It used a 24-hour recall format, asking participants to rate the worst severity of seven symptoms (fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain) during the past 24 hours. Each symptom was rated on a scale from 0 (Absent) to 10 (Worst Imaginable). The Total Symptom Score (TSS) was the sum of 7 symptoms (range: 0-70). 'No Change from Baseline' indicated stable symptoms (no improvement or worsening), negative change from Baseline indicated a reduction in symptom severity (improvement), and positive change from Baseline indicated an increase in symptom severity (worsening).

  5. Phase 2 (Arms 1, 2 and 3): Number of Participants Who Achieved a ≥ 50% Reduction in Total Symptom Score (TSS) at 12 and 24 Weeks

    Time frame: Week 12 (Cycle 5 Day 1), Week 24 (Cycle 9 Day 1)

    The proportion of study participants who experienced a reduction of at least 50% in their Total Symptom Score (TSS), as assessed using the Myelofibrosis Symptom Assessment Form (MFSAF v4.0), was evaluated at both 12 and 24 weeks relative to their baseline score.

  6. Phase 2 (Arms 1, 2 and 3): Number of Participants With Overall Splenic Response Rate (Overall SVR35)

    Time frame: Through Phase II completion, an average of 6 years

    Overall Splenic Response Rate (SVR35) was defined as the proportion of participants who achieved a reduction of at least 35% in spleen size from baseline, as measured by imaging (MRI or CT), at any point between Cycle 1 Day 1 and the End of Study Visit, whichever occurred first.

  7. Phase 2 (Arms 1, 2 and 3): Duration of Overall Splenic Response (Overall SVR35)

    Time frame: From first onset of splenic response until loss of response, assessed up to approximately 6 years

    Duration of Overall Splenic Response (overall SVR35) was defined as the time from the first occurrence of a at least 35% reduction in spleen volume from baseline until the earliest of the following: a reduction of less than 35% from baseline combined with an increase of more than 25% from the nadir in spleen volume (as measured by MRI or CT), or death. The nadir was defined as the lowest spleen volume recorded after baseline and up to the evaluation point at which the initial splenic response was achieved.

  8. Phase 2 (Cohorts 1A and 2A): Number of Participants With Splenic Response Rate (SVR35) at 12 and 24 Weeks

    Time frame: Week 12 (Cycle 5 Day 1), Week 24 weeks (Cycle 9 Day 1)

    Splenic Response Rate (SVR35) at 12 and 24 weeks was defined as the proportion of participants who achieved a reduction of at least 35% in spleen size from baseline, as determined by imaging (MRI or CT), following 12 and 24 weeks of treatment, respectively.

  9. Phase 2 (Cohorts 1A and 2A): Duration of Red Blood Cell (RBC) Transfusion Independence (TI) in Participants Who Enroll as Transfusion Dependent (TD)

    Time frame: From first onset of TI to earliest onset of loss of TI, assessed up to approximately 6 years

    Duration of Red Blood Cell (RBC) Transfusion Independence (TI) was defined as the longest continuous period during which participants, having achieved at least 12 weeks of transfusion independence, remained free from RBC transfusions.

  10. Phase 2 (Cohorts 1A and 2A): Early Anemic Response Rate in Participants Who Enroll as Transfusion Dependent (TD)

    Time frame: Through Phase II completion, an average of 6 years

    Early anemic response rate was defined as the proportion of participants who achieved an average increase of at least 1 g/dL in hemoglobin concentration over any rolling 8-week (56-day) period following baseline. This calculation was performed after applying the 14/3 day rule, which stipulates that hemoglobin measurements must be spaced at least 14 days apart, and that at least 3 such measurements are required within the 8-week window to ensure a reliable average. Importantly, this increase had to occur without any red blood cell (RBC) transfusions during the treatment period and up to the time of the latest hemoglobin assessment for each patient.

  11. Phase 2 (Cohorts 1B, 2B, and Arm 3): Number of Participants With Splenic Response Rate (SVR35) at 12 Weeks

    Time frame: Week 12 (Cycle 5 Day 1)

    Splenic Response Rate (SVR35) at Week 12 was defined as the proportion of participants who achieved a reduction of at least 35% in spleen size from baseline, as measured by imaging (MRI or CT), following 12 weeks of treatment.

  12. Phase 2 (Cohorts 1B, 2B, and Arm 3): Anemic Response Rate in Participants Who Enroll as Non-transfusion-dependent (Non-TD)

    Time frame: Through Phase II completion, an average of 6 years

    Anemic response was defined as a sustained average increase in hemoglobin concentration of at least 1.5 g/dL over any rolling 12-week (84-day) period following baseline. This calculation excluded periods involving red blood cell (RBC) transfusions and was performed after applying the 14/3-day rule for valid hemoglobin assessments. The response had to be maintained through to the most recent available hemoglobin measurement for each patient.

  13. Phase 2 (Arm 4): Percentage of Participants Who Achieve a ≥50% Reduction From Baseline in the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Total Score

    Time frame: Baseline, 12 weeks (Cycle 5, Day 1), 24 weeks (Cycle 9, Day 1)

    The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) is a patient-reported questionnaire designed to measure symptom burden in participants with myeloproliferative neoplasms (MPNs). Participants rate the severity of several symptoms (such as fatigue, night sweats, itching, abdominal discomfort, bone pain, early satiety, and others) over the past 24 hours. Each symptom is scored on a scale from 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be). The total score is the sum of all individual symptom scores, providing an overall measure of symptom burden. A 50% reduction in the MPN-SAF total score at 12 or 24 weeks means the patient's overall symptom burden has improved by half compared to their baseline (pre-treatment) score.

  14. Phase 2 (Arm 4): Partial Hematological Response Rate (PHR)

    Time frame: Over 2 consecutive cycles (rolling window) (1 cycle = 21 days)

    Partial Hematological Response Rate (PHR) was defined as the proportion of participants who met the following criteria over two consecutive cycles up to the last administration of study treatment:

    • Platelet count > 400-600 x 10^9/L
    • WBC count within normal range (i.e., ≤ 10 x 10^9/L)
    • Laboratory results confirmed after 1 cycle (after 3weeks)

  15. Phase 2 (Arm 4): Overall Hematological Response Rate (OHR)

    Time frame: Through Phase II completion, an average of 6 years

    Confirmed Overall Hematological Response (OHR) Rate was defined as the proportion of participants with either a confirmed complete or a partial hematological response at any time.

  16. Phase 2 (Arm 4): Duration of Overall Hematological Response Rate (OHR)

    Time frame: Through Phase II completion, an average of 6 years

    Duration of Overall Hematological Response (OHR) Rate was defined as the time from when the overall hematological response was first met until the time at which the overall hematological response was lost, i.e., the criteria for an overall hematological response (CHR or PHR) were not observed or death occurred, whichever came first.

  17. Phase 2 (Arm 4): Rate of Hemorrhagic and Thromboembolic (TE) Events

    Time frame: Through Phase II completion, an average of 6 years

    Rate of hemorrhagic and thromboembolic (TE) events was defined as the proportion of participants with hemorrhagic or thromboembolic events throughout the study.

  18. Phase 2 (All Arms): Maximum Observed Plasma Concentration (Cmax) of Pelabresib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points.

    Cmax was listed and summarized using descriptive statistics.

  19. Phase 2 (All Arms): Time to Reach Maximum Concentration (Tmax) of Pelabresib

    Time frame: Cycle 1 Day 14 (predose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points.

    Tmax was listed and summarized using descriptive statistics.

  20. Phase 2 (All Arms): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Pelabresib

    Time frame: Cycle 1 Day 14 (predose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points.

    Ctrough was listed and summarized using descriptive statistics.

  21. Phase 2 (All Arms): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Pelabresib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points.

    AUClast was listed and summarized using descriptive statistics.

  22. Phase 2 (All Arms): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Pelabresib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points.

    AUC0-8,ss was listed and summarized using descriptive statistics.

  23. Phase 2 (All Arms): Time of Last Measurable Concentration (Tlast) of Pelabresib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on Pelabresib plasma concentrations and actual sampling time points.

    Tlast was listed and summarized using descriptive statistics.

  24. Phase 2 (Arm 2 - Cohort 2A): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

    Cmax was listed and summarized using descriptive statistics.

  25. Phase 2 (Arm 2 - Cohort 2A): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

    Tmax was listed and summarized using descriptive statistics.

  26. Phase 2 (Arm 2 - Cohort 2A): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib

    Time frame: Cycle 1 Day 14 (predose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

    Ctrough was listed and summarized using descriptive statistics.

  27. Phase 2 (Arm 2 - Cohort 2A): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

    AUClast was listed and summarized using descriptive statistics.

  28. Phase 2 (Arm 2 - Cohort 2A): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

    AUC0-8,ss was listed and summarized using descriptive statistics.

  29. Phase 2 (Arm 2 - Cohort 2B): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

    Cmax was listed and summarized using descriptive statistics.

  30. Phase 2 (Arm 2 - Cohort 2B): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

    Tmax was listed and summarized using descriptive statistics.

  31. Phase 2 (Arm 2 - Cohort 2B): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

    Ctrough was listed and summarized using descriptive statistics.

  32. Phase 2 (Arm 2 - Cohort 2B): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

    AUClast was listed and summarized using descriptive statistics.

  33. Phase 2 (Arm 2 - Cohort 2B): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

    AUC0-8,ss was listed and summarized using descriptive statistics.

  34. Phase 2 (Arm 3): Maximum Observed Plasma Concentration (Cmax) of Ruxolitinib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

    Cmax was listed and summarized using descriptive statistics.

  35. Phase 2 (Arm 3): Time to Reach Maximum Concentration (Tmax) of Ruxolitinib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

    Tmax was listed and summarized using descriptive statistics.

  36. Phase 2 (Arm 3): Predose (Trough) Concentration at the End of a Dosing Interval (Ctrough) of Ruxolitinib

    Time frame: Cycle 1 Day 14 (predose, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

    Ctrough was listed and summarized using descriptive statistics.

  37. Phase 2 (Arm 3): Area Under the Concentration-Time Curve From Time Zero to the Last Observed Concentration (AUClast) of Ruxolitinib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

    AUClast was listed and summarized using descriptive statistics.

  38. Phase 2 (Arm 3): Area Under the Concentration-Time Curve From Time Zero to 8 Hours Post-dose at Steady State (AUC0-8,ss) of Ruxolitinib

    Time frame: Cycle 1 Day 14 (30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours post-dose). 1 cycle = 21 days.

    Pharmacokinetic (PK) parameters were calculated based on ruxolitinib plasma concentrations and actual sampling time points.

    AUC0-8,ss was listed and summarized using descriptive statistics.

Sponsors and collaborators

Lead sponsor

Constellation Pharmaceuticals

Industry

Collaborators

  • The Leukemia and Lymphoma Society

Registry information

Official study title

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)

Important dates

Study start
2014
Primary completion
2025
Study completion
2025
First posted
Jun 9, 2014
Registry last updated
Jun 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.